{
    "Trade/Device Name(s)": [
        "Yumizen C1200 Calcium AS",
        "Yumizen C1200 Creatinine Jaffe"
    ],
    "Submitter Information": "HORIBA ABX SAS",
    "510(k) Number": "K191396",
    "Predicate Device Reference 510(k) Number(s)": [
        "K123171",
        "K110530"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJY",
        "CGX"
    ],
    "Summary Letter Date": "May 22, 2019",
    "Summary Letter Received Date": "May 24, 2019",
    "Submission Date": "May 22, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1145",
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Calcium Test System",
        "Creatinine Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Calcium",
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 Clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetry",
        "Kinetic method (Jaffe method)"
    ],
    "Methodologies": [
        "Quantitative measurement procedures"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 Calcium AS and Yumizen C1200 Creatinine Jaffe reagents for quantitative measurement of calcium and creatinine in serum, plasma, and urine using colorimetric methods on the Yumizen C1200 analyzer",
    "Indications for Use Summary": "Yumizen C1200 Calcium AS and Creatinine Jaffe reagents are intended for the quantitative in vitro determination of calcium and creatinine in human serum, plasma, and urine to aid in the diagnosis and treatment of parathyroid, bone, and renal diseases and for monitoring renal dialysis",
    "fda_folder": "Clinical Chemistry"
}